DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
ADA621495
Title:
Vancomycin-Resistance Enterococci Infections in the Department of the Defense: Annual Report 2014
Descriptive Note:
Technical rept. Jan 2005-Dec 2014
Corporate Author:
NAVY AND MARINE CORPS PUBLIC HEALTH CENTER PORTSMOUTH VA EPIDATA CENTER DEPT
Report Date:
2015-07-22
Pagination or Media Count:
23.0
Abstract:
Vancomycin-resistant Enterococci VRE are Gram-positive cocci that are resistant to vancomycin and most commonly infect seriously ill patients that have prolonged hospital stays or antibiotic use. Hospital acquired VRE infections are associated with high rates of morbidity and mortality and are a concern for hospitals around the world. The objective of this annual retrospective report is to summarize the VRE infection burden in the Department of Defense DOD and the Department of the Navy DON for calendar year CY 2014. This summary includes demographic and clinical characteristics, antibiotic susceptibility patterns, prescription practices, and healthcare-associated HA infection metrics for all DOD and DON beneficiaries. Overall, the incidence rates of VRE infections in the general United States US and DOD are decreasing while increasing for the DON populations. VRE risk groups did not substantially change in 2014 as VRE continues to predominately affect elderly females and manifest as urinary tract infections UTIs. In addition, antibiotic susceptibility patterns did not substantially change in 2014. Daptomycin, linezolid and gentamicin remain viable treatments for VRE. HA infections have decreased in the last year but the overall exposure burden of VRE remains a major problem in the hospital setting. Improved infection control practices would help to minimize the spread of these infections.
Distribution Statement:
APPROVED FOR PUBLIC RELEASE
